Ursodiol
Active ingredient: Ursodiol
In short: Ursodiol tablets are indicated for the treatment of patients with primary biliary cholangitis (PBC).
What is Ursodiol used for?
Ursodiol tablets are indicated for the treatment of patients with primary biliary cholangitis (PBC).
Ursodiol dosage
The recommended adult dosage for ursodiol tablets in the treatment of PBC is 13 to 15 mg/kg/day administered in two to four divided doses with food. Dosing regimen should be adjusted according to each patient’s need at the discretion of the physician.
Liver function tests (γ-GT, alkaline phosphatase, AST, ALT) and bilirubin levels should be monitored every month for three months after start of therapy, and every six months thereafter .
The ursodiol 500 mg scored tablet can be broken in halves to provide recommended dosage.
To break ursodiol 500 mg scored tablet easily, place the tablet on a flat surface with the scored section on top. Hold the tablet with your thumbs placed close to the scored part of the tablet (groove). Then apply gentle pressure and snap the tablet segments apart (segments breaking incorrectly should not be used). The segments should be washed down unchewed, with water, keeping the segments in the mouth can reveal a bitter taste. Due to the bitter taste, segments should be stored separately from whole tablets. .
How to take Ursodiol — instructions & advice from the label
Enteroliths in Patients with Risk for Intestinal Stenosis or Stasis
Advise patients or their caretaker(s) to notify their healthcare provider if they experience obstructive gastrointestinal symptoms due to the risk of enteroliths .
Drug Interactions
Patients should be informed that absorption of ursodiol may be reduced if they are taking bile acid sequestering agents, such as cholestyramine and colestipol, aluminum-based antacids, or drugs known to alter the metabolism of cholesterol .
Rx Only
Manufactured for:
Par Health USA Woodcliff Lake, NJ 07677 U.S.A.
Packaged and Distributed by:
MAJOR® PHARMACEUTICALS
Indianapolis, IN 46268 USA
Refer to package label for Distributor's NDC Number
Distributed By:
Cardinal Health
Dublin, OH 43017
L58749531125
Product of Italy Made in India Neutral Code: TN/DRUGS/TN00002121 © 2026 Par Health, Inc. or one of its affiliates.
OS412-01-74-04 Revised: 05/2026
Warnings & precautions
Do not take this medicine if: Patients with complete biliary obstruction and known hypersensitivity or intolerance to ursodiol or any of the components of the formulation.
Liver function tests (γ-GT, alkaline phosphatase, AST, ALT) and bilirubin levels should be monitored every month for three months after start of therapy, and every six months thereafter. This monitoring will allow the early detection of a possible deterioration of the hepatic function. Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant in patients with stable historical liver function test levels.
Caution has to be exercised to maintain the bile flow of the patients taking ursodiol.
There have been rare postmarketing reports of Ursodiol tablets-treated patients who developed enteroliths (bezoars) resulting in obstructive symptoms that required surgical intervention. These patients had medical conditions that predisposed them to intestinal stenosis or stasis (e.g., surgical enteroanastomoses, Crohn's disease). If a patient presents with obstructive gastrointestinal symptoms, hold Ursodiol tablets until a clinical evaluation has been conducted.
Ursodiol side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The following table summarizes the adverse reactions observed in two placebo-controlled clinical trials.
ADVERSE REACTIONS | VISIT AT 12 MONTHS | VISIT AT 24 MONTHS
UDCA n (%) | Placebo n (%) | UDCA n (%) | Placebo n (%)
Diarrhea | --- | --- | 1 (1.32) | ---
Elevated creatinine | --- | --- | 1 (1.32) | ---
Elevated blood glucose | 1 (1.18) | --- | 1 (1.32) | ---
Leukopenia | --- | --- | 2 (2.63) | ---
Peptic ulcer | --- | --- | 1 (1.32) | ---
Skin rash | --- | --- | 2 (2.63) | ---
Thrombocytopenia | --- | --- | 1 (1.32) | ---
Note: Those adverse reactions occurring at the same or higher incidence in the placebo as in the UDCA group have been deleted from this table (this includes diarrhea and thrombocytopenia at 12 months, nausea/vomiting, fever and other toxicity).
UDCA = Ursodeoxycholic acid = Ursodiol
In a randomized, cross-over study in sixty PBC patients, seven patients (11.6%) reported nine adverse reactions: abdominal pain and asthenia (1 patient), nausea (3 patients), dyspepsia (2 patients) and anorexia and esophagitis (1 patient each). One patient on the twice a day regimen (total dose 1,000 mg) withdrew due to nausea. …
Drug interactions
Bile acid sequestering agents such as cholestyramine and colestipol may interfere with the action of ursodiol by reducing its absorption.
Aluminum-based antacids have been shown to adsorb bile acids in vitro and may be expected to interfere with ursodiol in the same manner as the bile acid sequestering agents.
Estrogens, oral contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) increase hepatic cholesterol secretion and encourage cholesterol gallstone formation and hence may counteract the effectiveness of ursodiol.
About this medicine
Ursodiol Tablets, USP 250 mg are available as a film-coated tablet for oral administration. Ursodiol Tablets, USP 500 mg are available as a scored film-coated tablet for oral administration. Ursodiol, USP (ursodeoxycholic acid, UDCA) is a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the biles of certain species of bears. It is white or almost white crystalline powder freely soluble in ethanol, slightly soluble in acetone, and practically insoluble in Methylene chloride and water. The chemical name of ursodiol, USP is 3α,7ß-dihydroxy-5ß-cholan-24-oic acid (C24H40O4). Ursodiol, USP has a molecular weight of 392.6. Its structure is shown below.
Inactive ingredients: caprylic/capric triglycerides, copovidone, hypromellose, microcrystalline cellulose, magnesium stearate, povidone, polydextrose, polyethylene glycol 3350, sodium starch glycolate type A and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 61dcaec8-3acb-4ef0-afde-65a66e99afa7. Read the full official label on DailyMed.